OPTIFAST® MEAL REPLACEMENT PROGRAM FOR THE TREATMENT OF OBESITY- A COST-EFFECTIVENESS ASSESSMENT FROM THE EMPLOYER PERSPECTIVE IN THE USA
Author(s)
Perugini M1, Marczewska AM1, Araujo Torres K1, Rasouli B2, Nuijten M3
1Nestle Health Science, Vevey, Switzerland, 2Karolinska Institutet, Stockholm, Sweden, 3A2M - Minerva, Jisp, The Netherlands
OBJECTIVES : This study compares potential cost savings over 3 years of the OPTIFAST® program with “no intervention”, liraglutide and naltrexone/bupropion medications from an employer perspective in the USA. The OPTIFAST® program is a medically supervised weight management intervention consisting of nutritional and behavioral counselling and a 12-16 week phase of total meal replacement. In a clinical trial with 8,296 participants with obesity, OPTIFAST®
Conference/Value in Health Info
2018-05, ISPOR 2018, Baltimore, MD, USA
Value in Health, Vol. 21, S1 (May 2018)
Code
PSY49
Topic
Economic Evaluation
Topic Subcategory
Cost-comparison, Effectiveness, Utility, Benefit Analysis
Disease
Cardiovascular Disorders, Diabetes/Endocrine/Metabolic Disorders
Your browser is out-of-date
ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now